An International Collaborative Study to establish the WHO 2nd International Standard for High Molecular Weight Urokinase: Communication from SSC of the ISTH

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 3, 2014, Pages 415-417

  Longstaff, C ^a   Thelwell, C ^a   Rigsby, P ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE;

ARTICLE; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ALBUMINS; CALIBRATION; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONAL COOPERATION; MOLECULAR WEIGHT; REFERENCE STANDARDS; TEMPERATURE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; WORLD HEALTH;

EID: 84896771304     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12483     Document Type: Article

References (13)

1. Gurewich V. Fibrinolytic mechanisms of tPA, prouPA, mutant prouPA and their implications for therapeutic thrombolysis. Cardiovasc Eng Technol 2013; 4: 328-38.
2. Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. PLoS ONE 2011; 6: e21999.
3. Gurewich V. Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action. Semin Thromb Hemost 1988; 14: 110-15.
4. Gates J, Hartnell GG. When urokinase was gone: commentary on another year of thrombolysis without urokinase. J Vasc Interv Radiol 2004; 15: 1-5.
5. Gaffney PJ, Heath AB. A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA). Thromb Haemost 1990; 64: 398-401.
6. Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue plasminogen activator (tPA). J Thromb Haemost 2012; 10: 2354-60.
7. Daas A. CombiStats v4.0, www.combistats.eu.: EDQM, Council of Europe. 2008.
8. Finney D. Statistical Methods in Biological Assay. London: Charles Griffen, 1978.
9. European Commission. Alteplase for injection. Monograph, European Pharmacopoeia: European Commission. 2013, 2007:1170 corrected 8.0.
10. Grubbs FE. Procedures for detecting outlying observations in samples. Technometrics 1969; 11: 1-21.
11. Kirkwood TB. Design and analysis of accelerated degradation tests for the stability of biological standards III. Principles of design. J Biol Stand 1984; 12: 215-24.
12. Thelwell C, Marszal E, Rigsby P, Longstaff C. An international collaborative study to establish the WHO 1st international standard for alpha-1-antitrypsin. Vox Sang 2011; 101: 83-9.
13. Jameson GW, Roberts DV, Adams RW, Kyle WS, Elmore DT. Determination of the operational molarity of solutions of bovine alpha-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem J 1973; 131: 107-17.